B Group
DALLAS, TXfiles as B Group, Inc.
$176m in 18 US stocks at the end of 30 June 2026. The top 10 are 79.2% of the money. It changed about 16.5% of the portfolio this quarter.
Value
$176m
Stocks
18
Top 10 share
79.2%
Turnover
16.5%
What changed this quarter
New
Bought for the first time this quarter.
- Faeth TherapeuticsFTH8.7% of the fund
Added
Bought more of a stock they already held.
- NRX PharmaceuticalsNRXP9.5% of the fund+36%
- Structure TherapeuticsGPCR4.3% of the fund+10%
- Aura BiosciencesAURA3.1% of the fund+28%
- Foghorn TherapeuticsFHTX0.6% of the fund+96%
Cut
Sold some of their stake.
- Spyre TherapeuticsSYRE3.5% of the fund-30%
Sold out
Sold their entire stake.
- Apogee TherapeuticsAPGE-100%
- Soleno Therapeutics-100%
- Replimune GroupREPL-100%
Holdings
- Cellectis S ACLLS
- Share
- 5.6%
- Value
- $10m
- Shares
- 3,281,501
Held
- ZAI LABZLAB
- Share
- 4.9%
- Value
- $9m
- Shares
- 450,646
Held
- Structure TherapeuticsGPCR
- Share
- 4.3%
- Value
- $8m
- Shares
- 140,000
+10%
- Bright Minds BiosciencesDRUG
- Share
- 2.7%
- Value
- $5m
- Shares
- 67,500
Held
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Adma BiologicsADMA | 15.5% | $27m | 3,262,542 | Held |
| Palisade BIOPALI | 13.5% | $24m | 11,414,285 | Held |
| NRX PharmaceuticalsNRXP | 9.5% | $17m | 4,091,767 | +36% |
| Faeth TherapeuticsFTH | 8.7% | $15m | 610,169 | New |
| Taysha Gene TherapiesTSHA | 7.0% | $12m | 1,800,556 | Held |
| Praxis Precision MedicinesPRAX | 6.3% | $11m | 33,237 | Held |
| Cellectis S ACLLS | 5.6% | $10m | 3,281,501 | Held |
| ZAI LABZLAB | 4.9% | $9m | 450,646 | Held |
| Structure TherapeuticsGPCR | 4.3% | $8m | 140,000 | +10% |
| Oruka TherapeuticsORKA | 4.1% | $7m | 75,000 | Held |
| Iovance BiotherapeuticsIOVA | 3.5% | $6m | 1,500,000 | Held |
| Spyre TherapeuticsSYRE | 3.5% | $6m | 70,000 | -30% |
| Aura BiosciencesAURA | 3.1% | $5m | 764,243 | +28% |
| Assembly BiosciencesASMB | 2.7% | $5m | 175,706 | Held |
| Bright Minds BiosciencesDRUG | 2.7% | $5m | 67,500 | Held |
| Ultragenyx PharmaceuticalRARE | 2.6% | $5m | 135,000 | Held |
| Sight SciencesSGHT | 2.1% | $4m | 970,000 | Held |
| Foghorn TherapeuticsFHTX | 0.6% | $976,000 | 200,000 | +96% |
Options (1)
- Invesco QQQ TR
- Type
- Put
- Value
- $37m
- Contracts
- 50,000
| Company | Type | Value | Contracts |
|---|---|---|---|
| Invesco QQQ TR | Put | $37m | 50,000 |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 52.2% since 30 June 2025.
Where the money is
Health care85.3%
Other14.7%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.